In this study, variable reduction and selection conducted on the training set identified tumor size, Ki-67, molecular subtype, targeted therapy, and chemotherapy regimen as significant predictors of tpCR in NAC for LABC patients. The gene discussed is MKI67; the disease is neoplasm.